Phase 3 study of nilotinib vs imatinib in Chinese patients with newly diagnosed chronic myeloid leukemia in chronic phase: ENESTchina

Blood

Volumn 125, Issue 18, 2015, Pages 2771-2778

  Wang, Jianxiang ^a   Shen, Zhi Xiang ^b   Saglio, Giuseppe ^c   Jin, Jie ^d   Huang, He ^d   Hu, Yu ^e   Du, Xin ^f   Li, Jianyong ^g   Meng, Fanyi ^h   Zhu, Huanling ⁱ   Hu, Jianda ^j   Wang, Jianmin ^k   Hou, Ming ^l   Hertle, Sabine ^m   Menssen, Hans D ^m   Ortmann, Christine Elke ^m   Tribouley, Catherine ^m   Yuan, Ye ⁿ   Baccarani, Michele ^o   Huang, Xiaojun ^p  

^a INSTITUTE OF HEMATOLOGY AND BLOOD DISEASES HOSPITAL   (China)

^b SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF TURIN   (Italy)

^d ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^e UNION HOSPITAL   (China)

^f GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^g THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^h SOUTHERN MEDICAL UNIVERSITY   (China)

ⁱ SICHUAN UNIVERSITY   (China)

^j FUJIAN MEDICAL UNIVERSITY   (China)

^k SECOND MILITARY MEDICAL UNIVERSITY   (China)

^l SHANDONG UNIVERSITY   (China)

^m NOVARTIS PHARMA AG   (Switzerland)

ⁿ Limited   (China)

^o UNIVERSITY OF BOLOGNA   (Italy)

^p PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CALCIUM; CHOLESTEROL; GLUCOSE; HEMOGLOBIN; IMATINIB; MAGNESIUM; NILOTINIB; PHOSPHATE; POTASSIUM; SODIUM; TRIACYLGLYCEROL; TRIACYLGLYCEROL LIPASE; 4-METHYL-N-(3-(4-METHYLIMIDAZOL-1-YL)-5-(TRIFLUOROMETHYL)PHENYL)-3-((4-PYRIDIN-3-YLPYRIMIDIN-2-YL)AMINO)BENZAMIDE; ANTINEOPLASTIC AGENT; BENZAMIDE DERIVATIVE; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BLAST CELL CRISIS; BONE MARROW DEPRESSION; BRAIN HEMORRHAGE; CALCIUM BLOOD LEVEL; CANCER CHEMOTHERAPY; CANCER PATIENT; CHINA; CHINESE; CHOLESTEROL BLOOD LEVEL; CHRONIC MYELOID LEUKEMIA; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; CYTOGENETICS; DIARRHEA; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED CANCER; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EYELID EDEMA; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERBILIRUBINEMIA; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; LEUKEMIA REMISSION; MAGNESIUM BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METAPHASE; MYALGIA; NEUTROPENIA; NONHODGKIN LYMPHOMA; PHASE 3 CLINICAL TRIAL; PHILADELPHIA CHROMOSOME POSITIVE CELL; PHOSPHATE BLOOD LEVEL; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SODIUM BLOOD LEVEL; THROMBOCYTOPENIA; THROMBOCYTOSIS; TREATMENT OUTCOME; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; ADJUVANT THERAPY; ADOLESCENT; CLINICAL TRIAL; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LEUKEMIA, MYELOID, CHRONIC-PHASE; MIDDLE AGED; MULTICENTER STUDY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; BENZAMIDES; CHINA; FEMALE; HUMANS; IMATINIB MESYLATE; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LEUKEMIA, MYELOID, CHRONIC-PHASE; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; PIPERAZINES; PYRIMIDINES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84929494071     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-09-601674     Document Type: Article

References (31)

1. Tasigna(R) [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2014.
2. Gleevec(R) [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2013.
3. Saglio G, Kim DW, Issaragrisil S, et al; ENESTnd Investigators. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010;362(24): 2251-2259.
4. Kantarjian HM, Hochhaus A, Saglio G, et al. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol. 2011;12(9):841-851.
5. Larson RA, Hochhaus A, Hughes TP, et al. Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. Leukemia. 2012; 26(10):2197-2203.
6. Hughes TP, Saglio G, Kantarjian HM, et al. Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib. Blood. 2014;123(9):1353-1360.
7. Hughes TP, le Coutre PD, Jootar S, et al. ENESTnd 5-year follow-up: continued benefit of frontline nilotinib (NIL) compared with imatinib (IM) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) [abstract]. Haematologica. 2014;99. Abstract s677.
8. Baccarani M, Cortes J, Pane F, et al; European LeukemiaNet. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol. 2009;27(35):6041-6051.
9. Ng KP, Hillmer AM, Chuah CT, et al. A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer. Nat Med. 2012;18(4): 521-528.
10. Katagiri S, Tauchi T, Umezu T, et al. High frequencies of switching to 2nd TKIs and failure to maintain standard imatinib dose in Japanese CML patients with BIM genetic variants. [abstract]. Blood. 2013;122(21). Abstract 4021.
11. Larson RA, Kim DW, Jootar S, et al. ENESTnd 5-y update: long-term outcomes of patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) treated with frontline nilotinib (NIL) vs imatinib (IM) [abstract]. J Clin Oncol. 2014;32(5s). Abstract 7073.
12. Hehlmann R, Müller MC, Lauseker M, et al. Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV. J Clin Oncol. 2014;32(5):415-423.
13. Rousselot P, Charbonnier A, Cony-Makhoul P, et al. Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease. J Clin Oncol. 2014;32(5):424-430.
14. Branford S, Yeung DT, Ross DM, et al. Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML. Blood. 2013;121(19):3818-3824.
15. Hasford J, Baccarani M, Hoffmann V, et al. Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score. Blood. 2011;118(3):686-692.
16. Guilhot J, Baccarani M, Clark RE, et al. Definitions, methodological and statistical issues for phase 3 clinical trials in chronic myeloid leukemia: a proposal by the European LeukemiaNet. Blood. 2012;119(25):5963-5971.
17. Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122(6):872-884.
18. Hughes TP, Hochhaus A, Branford S, et al; IRIS investigators. Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS). Blood. 2010; 116(19):3758-3765.
19. Mendizabal AM, Garcia-Gonzalez P, Levine PH. Regional variations in age at diagnosis and overall survival among patients with chronic myeloid leukemia from low and middle income countries. Cancer Epidemiol. 2013;37(3):247-254.
20. Sokal JE, Cox EB, Baccarani M, et al. Prognostic discrimination in "good-risk" chronic granulocytic leukemia. Blood. 1984;63(4):789-799.
21. O'Brien SG, Guilhot F, Larson RA, et al; IRIS Investigators. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348(11):994-1004.
22. Giles FJ, Mauro MJ, Hong F, et al. Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis. Leukemia. 2013;27(6):1310-1315.
23. Kim TD, Rea D, Schwarz M, et al. Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib. Leukemia. 2013;27(6):1316-1321.
24. Rea D, Gautier J, Breccia M, et al. Incidence of hyperglycemia by 3 years in patients (Pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with nilotinib (NIL) or imatinib (IM) in ENESTnd [abstract]. Blood. 2012;120(21). Abstract 1686.
25. Rea D, Mirault T, Cluzeau T, et al. Early onset hypercholesterolemia induced by the 2nd-generation tyrosine kinase inhibitor nilotinib in patients with chronic phase-chronic myeloid leukemia. Haematologica. 2014;99(7):1197-1203.
26. National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE), version 3.0. 2006.
27. Jellinger PS, Smith DA, Mehta AE, et al; AACE Task Force for Management of Dyslipidemia and Prevention of Atherosclerosis. American Association of Clinical Endocrinologists' guidelines for management of dyslipidemia and prevention of atherosclerosis. Endocr Pract. 2012; 18(suppl 1):1-78.
28. Eckel RH, Jakicic JM, Ard JD, et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(25 suppl 2):S76-S99.
29. Stone NJ, Robinson JG, Lichtenstein AH, et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(25 suppl 2):S1-S45.
30. Perk J, De Backer G, Gohlke H, et al; European Association for Cardiovascular Prevention & Rehabilitation (EACPR); ESC Committee for Practice Guidelines (CPG). European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) [published correction appears in Eur Heart J. 2012;33(17):2126]. Eur Heart J. 2012; 33(13):1635-1701.
31. Haouala A, Widmer N, Duchosal MA, Montemurro M, Buclin T, Decosterd LA. Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib. Blood. 2011;117(8):e75-e87.